Skip to Content

'
Peter Y. Kim, MD, FACC

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004 Texas A&M University, College Station, TX, MD, Medicine
2002 Texas A&M University, College Station, TX, BS, Biomedical Science

Postgraduate Training

2008-2010 Cardiology Externship, Cardiology, University Medical and Dental Schools of New Jersey and Cardiovascular Associates of Delaware Valley, Various, NJ
2008-2009 Hospital Extern, New Jersey Community Hospitals, Various, NJ
2007-2010 Clinical Fellowship, Cardiovascular, UMDNJ-Cooper University Hospital, Camden, NJ
2004-2007 Clinical Residency, Internal Medicine, UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ

Board Certifications

10/2011 Board of Echocardiography
10/2010 Cardiovascular Disease
12/2009 Board of Nuclear Cardiology
8/2007 American Board of Internal Medicine

Honors and Awards

2012 Clinical Safety and Effectiveness Program Graduate (Team Leader) Session 16, The University of Texas MD Anderson Cancer Center
2009-2010 Chief Cardiology Fellow, Cooper University Hospital
1998-2004 Medical Science Scholar, Texas A&M University
1998-2002 President's Endowed Scholarship, Texas A&M University
1998 National Merit Scholarship Recipient, Tenet Healthcare Corporation

Selected Publications

Book Chapters

1. Kim P, Vejpongsa P, Yeh, E. Cancer Therapy-induced Cardiomyopathy. In: Essential Cardiology: Principles & Practice, 3. Ed(s) Clive Rosendorff. Springer New York, 715-725, 2013. ISBN: 9781461467047.
2. Kim P. Chemotherapy Induced Cardiomyopathy. In: Cancer Rehabilitation Medicine Quick Reference Book, 1. Ed(s) Ralph Buschbacher, 2013. ISBN: 1936287048.
3. Kim, PY. Long QT and Torsades de Pointes. In: 5 Minute ICU Consults. Lippincott Williams & Wilkins: USA, 2011. ISBN: 1605472166.

Letters to the Editor

1. Yusuf SW, Kim P, Durand JB. Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer. New England Journal of Medicine 364(24):2367, 6/2011.

Last updated: 6/29/2016